Quantcast

Latest Gene therapy Stories

2014-05-22 08:29:48

In Addition, Toca 511 Clinical Data to be Presented at American Society of Clinical Oncology Annual Meeting SAN DIEGO, May 22, 2014 /PRNewswire/ -- Tocagen Inc. today announced multiple scientific contributions at the American Society of Gene and Cell Therapy (ASGCT) 17(th) Annual Meeting, held May 21 to 24, 2014 at the Marriott Wardman Park in Washington, DC. At the ASGCT Annual Meeting, data from clinical and preclinical studies of Toca 511 will be presented in two podium presentations:...

2014-05-14 08:31:21

RICHMOND, Calif., May 14, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that data from clinical, preclinical and research-stage programs focused on the development of ZFP Therapeutics(®) will be presented at the 17th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). Fourteen oral and poster presentations, given by Sangamo scientists and their academic collaborators, will detail data from Sangamo's therapeutic and research programs...

2014-05-13 08:33:50

Gene therapy leader will house business operations and manufacturing in a growing and dynamic biotech hub PHILADELPHIA, May 13, 2014 /PRNewswire/ -- Spark Therapeutics, a late-stage company developing gene-based medicines for a wide range of debilitating diseases, announced today that it has signed a real estate agreement to open its permanent headquarters in West Philadelphia. Spark, which was spun out of Children's Hospital of Philadelphia in October 2013 along with a $50 million...

2014-05-05 12:29:33

MOUNTAIN VIEW, Calif., May 5, 2014 /PRNewswire/ -- Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced that it has partnered with Vectalys SAS to combine Clontech's Living Colors® fluorescent protein and Tet-On® 3G technologies with Vectalys' expertise in providing the highest quality ready-to-use lentiviral particles as vectors for gene delivery. http://photos.prnewswire.com/prnvar/20131021/SF99259LOGO Carol Lou, General Manager of Clontech...

2014-05-05 08:28:53

TARRYTOWN, N.Y. and MENLO PARK, Calif., May 5, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Avalanche Biotechnologies, Inc., today announced the formation of a broad collaboration to discover, develop and commercialize novel gene therapy products for the treatment of ophthalmologic diseases. The collaboration covers novel gene therapy vectors and proprietary molecules, discovered jointly by Avalanche and Regeneron, and developed using the Avalanche Ocular...

2014-04-29 09:52:38

New research looking at the success of clinical trials of stem cell therapy shows that trials appear to be more successful in studies where there are more discrepancies in the trial data. Researchers from Imperial College London conducted a meta-analysis of 49 randomised controlled trials of bone marrow stem cell therapy for heart disease. The study, published today in the British Medical Journal, identified and listed over 600 discrepancies within the trial reports. Discrepancies were...

2014-04-29 08:36:49

GULF SHORES, Ala., April 29, 2014 /PRNewswire/ -- If successful, Neuralgene's (http://www.neuralgene.com) PRCN-323 treatment could significantly change the prognosis for everyone with the rare genetic disorder known as adrenoleukodystrophy, or ALD. The biotech company has recently celebrated a series of early successes in the treatment of other neurological conditions like ALS (Lou Gehrig's disease). Founder and CEO Jason Williams, M.D., believes his team is on the path toward a cure...

Existing Cochlear Technology Used To Re-grow Auditory Nerves
2014-04-24 03:24:49

[ Watch The Video: Bionic Ear Delivers DNA To Regrow Auditory Nerve Cells ] University of New South Wales Researchers at UNSW Australia have for the first time used electrical pulses delivered from a cochlear implant to deliver gene therapy, thereby successfully regrowing auditory nerves. The research also heralds a possible new way of treating a range of neurological disorders, including Parkinson's disease, and psychiatric conditions such as depression through this novel way...

2014-04-22 12:30:18

- Proceeds will Further Strengthen Avalanche's Proprietary BioFactoryTM Platform and Advance Clinical Program in Wet Age-Related Macular Degeneration - MENLO PARK, Calif., April 22, 2014 /PRNewswire/ -- Avalanche Biotechnologies, Inc, a leader in the development of innovative gene therapies for serious eye diseases such as wet age-related macular degeneration (AMD), today announced the successful completion of a $55 million Series B financing. New investors were led by Venrock, and...

2014-04-08 12:30:51

DUBLIN, April 8, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/fv78n3/cardiovascular) has announced the addition of a new report "Cardiovascular Drug Delivery - Technologies, Markets and Companies" [http://www.researchandmarkets.com/research/fv78n3/cardiovascular ] to their offering. <start_newscom> (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Drug delivery to the cardiovascular system is different from...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related